Social Cognition and Emotional Assessment differentiates frontotemporal dementia from depression

Maxime Bertoux,1,2,3,4 Marine Delavest,5,6 Leonardo Cruz de Souza,1,2,3,4 Aurélie Funkiewiez,3,4 Jean-Pierre Lépine,5,6 Philippe Fossati,7 Bruno Dubois,1,2,3,4 Marie Sarazin1,2,3,4

ABSTRACT

Background Behavioural variant of frontotemporal dementia (bvFTD) is a neurodegenerative disease that is clinically characterised by progressive behavioural changes and social interpersonal dysfunctions. Its diagnosis remains a clinical challenge, and depression is one of the main causes of misdiagnoses due to the prevalence of apathy in bvFTD.

Objective To evaluate the sensitivity and specificity of the Social Cognition and Emotional Assessment (SEA) and the mini-SEA for differentiating bvFTD from major depressive disorder (MDD).

Methods Scores for the SEA and mini-SEA for 37 patients with bvFTD (divided into subgroups of 17 with early bvFTD and 20 with moderate bvFTD according to the normal range of the Mattis Dementia Rating Scale), 19 MDD patients and 30 control subjects were compared to define the discrimination power of these tools compared with other standard neuropsychological tests.

Results SEA and mini-SEA scores were significantly lower for both the early and moderate bvFTD groups compared with control subjects and the MDD group, and very few scores overlapped between patients in the bvFTD subgroups and patients in the MDD and control subgroups. SEA and mini-SEA scores distinguished early bvFTD from MDD with sensitivity and specificity rates above 94%.

Conclusion Unlike standard executive neuropsychological tests, SEA and the mini-SEA can differentiate MDD from bvFTD in the early stages of the disease. The mini-SEA is an easy tool that can be utilised in neurological or psychiatric departments.

The behavioural variant of frontotemporal lobe degeneration (bvFTD) is a clinical syndrome involving focal atrophy that occurs predominantly in the frontal and temporal lobes and is associated with heterogeneous underlying pathologies.1 2 In the absence of definitive biomarkers, the diagnosis is currently based on clinical criteria, which were recently revised.3 4 Symptoms are characterised by behavioural disinhibition, impaired social interaction, apathy or inertia, loss of empathy or sympathy;5 stereotyped or compulsive behaviour, and hyperorality or dietary changes; these factors are usually assessed using informant based interviews such as the Frontal Behavioural Inventory.5 In addition, neuropsychological assessments can highlight executive impairments, and some functions can be relatively spared or even normal, such as episodic memory, language, visuospatial functions and praxis.1 Conventional brain imaging tools are sometimes not sensitive enough for diagnostic validation in the early stage of the disease.5 The symptoms are quite insidious and can sometimes mimic psychiatric disorders. Thus diagnosing bvFTD remains a clinical challenge; furthermore, bvFTD patients may be misdiagnosed with psychiatric related disorders, such as depression, or they may be underdiagnosed or even be considered ‘healthy’.5 6

To improve diagnostic accuracy, tools such as tests of theory of mind have been proposed to assess social and emotional cognition, especially when classic executive tests show few abnormalities or normal performances.9-14 Although these tests have demonstrated effectiveness in distinguishing bvFTD patients from controls, their ability to discriminate bvFTD from depressive patients are not well known. As depression is one of the main misdiagnoses of bvFTD,7 8 15-17 it is essential to develop clinical tools that are able to differentiate bvFTD from major depressive disorder (MDD).

In the present study, we studied the ability of the Social Cognition and Emotional Assessment (SEA)14 and its shorter version, the mini-SEA, to differentiate MDD from bvFTD at both early and moderate stages.

METHODS

Subjects Thirty-seven patients in the early or moderate stages of bvFTD, 19 patients with MDD and 30 controls were recruited for the study.

All bvFTD patients were evaluated at the Memory and Alzheimer’s Institute at the Pitie-Salpêtrière Hospital, Paris, France. Each patient’s final diagnosis was established by FTD experts after multidisciplinary clinical meetings with neuropsychologists and neurologists. bvFTD patients were enrolled if they fulfilled the Lund and Manchester criteria for diagnosing bvFTD.3 10 All patients presented prominent changes in personality and social behaviour that were validated by their caregivers. All patients also underwent a standard neuropsychological examination, including the Mini-Mental State Examination (MMSE) and the Mattis Dementia Rating Scale (MDRS)13 for general cognitive functioning, the Frontal Assessment Battery (FAB),10 a verbal fluency test (semantic with animals and phonemic with the letter M in 1 min),
the modified Wisconsin Card Sorting Task (WCST) for executive functions, the Free And Cued Selective Reminding Test for verbal episodic memory, a praxis evaluation and a word denomination task for language evaluation. Structural MRI and single photon emission computed tomography (SPECT) imaging examinations were performed for all patients; frontotemporal atrophy was identified on MRI and/or frontal hypoperfusion was detected in the SPECT images. Patients that presented with any of the following symptoms were not included in the study: (1) language deficit suggesting progressive non-fluent aphasia or semantic dementia, (2) a systemic illness that could interfere with cognitive functioning, (3) vascular lesions validated using MRI or neurological history suggesting vascular dementia or (4) a motor neuron disease. To improve diagnostic accuracy, all patients had at least one 18 month follow-up in the memory clinic of the Pitié-Salpêtrière Hospital to validate the diagnosis according to their clinical evolution.

We defined two subgroups of bvFTD patients according to their cognitive performance on the MDRS. This test is sensitive to fronto-dysfunctions and is considered very useful for the cognitive assessment of bvFTD patients and for tracking disease progression. The early bvFTD subgroup (n=17) was defined as those receiving an MDRS score in the normal range (from 151 to 141, depending on age and educational level). The moderate bvFTD subgroup (n=20) was defined as those receiving an MDRS score below the normal range (from 92 to 151, depending on age and educational level). We used French normative data for the MDRS.

Nineteen patients with MDD were assessed at the Adult Psychiatry Departments of the Fernand-Widal—Lariboisière Hospital and the Pitié-Salpêtrière Hospital. Diagnoses were made according to the following criteria: (a) fulfilling the DSM-IV criteria for MDD and (b) obtaining a Montgomery and Asberg Depression Rating Scale (MDARS) score $\geq$30. All patients were assessed by experienced psychiatrists. Exclusion criteria were: (1) a history of substance abuse, (2) a history of neurological disorders, (3) systemic illnesses that could interfere with cognitive functioning and (4) a history or evidence of psychotic symptoms or concomitant psychiatric disorders. All depressed patients underwent a reduced cognitive assessment that included the MMSE, FAB, a verbal morphological frequency test and the modified WCST. Twenty-one patients were originally included. Two patients were eliminated from the study after a diagnostic change when a manic episode occurred post-evaluation. Seventeen patients were treated with selective serotonin reuptake inhibitors or serotonin—norepinephrine reuptake inhibitors, seven with tetracyclic antidepressants and one with agomelatine. In addition, 11 patients took typical neuroleptic drugs (phenothrowine or cyamazine).

Thirty healthy control subjects, matched for age and education level, were included according to the following criteria: (1) an MMSE score $\geq$27/30 and a FAB score $\geq$16/18, (2) no history of neurological or psychiatric disorders and (3) no memory complaint or cognitive impairment.

For patients, all clinical data were obtained during the routine clinical work-up in the neurology and psychiatric departments and were extracted solely for the purpose of this study. Thus, according to French legislation, explicit informed consent was waived. However, the regulation concerning electronic filing was followed, and both patients and their relatives were informed that individual data may be used in retrospective clinical research studies. For healthy control subjects, the study was approved by the ethics committee for the protection of persons of the Pitié-Salpêtrière Hospital. All controls received oral and written information, and we obtained written informed consent before their participation.

Social Cognition and Emotional Assessment

All subjects underwent the same procedure.

The SEA consists of five subtests and provides six weighted composite scores: (1) a facial emotion recognition test (from Ekman pictures; scored from 0 to 15) in which patients must identify which emotion is being expressed, (2) a shortened version of the Faux Pas recognition test (scored from 0 to 15) that evaluates theory of mind, (3) a behavioural control test (scored from 0 to 5) in which patients must learn to apply a strategy of choice and to modify their choice based on monetary reward, (4) a reversal learning and extinction test (adapted from Roll26 and scored from 0 to 5) in which patients must reverse a pattern of reinforced choice after contingencies are unexpectedly reversed and (5) an apathy scale from Starkstein27 (scored from 0 to 15). A general composite score was then calculated.

We defined a mini-SEA comprising the sum of the facial emotion recognition and the Faux Pas test scores, which were validated in a previous study, to be able to accurately discriminate bvFTD from controls or patients with Alzheimer’s disease (AD). The estimated test completion time for the mini-SEA was 50 min. We chose not to include the apathy subscore as part of the mini-SEA because apathy is common to both MDD and bvFTD.28 The behavioural control and reversal learning and extinction tests were not included in the mini-SEA because these tasks had a lower discriminating power between bvFTD and controls or AD patients.

Statistical analysis

The normality of the demographic and neuropsychological data and of the SEA performances for all four groups was assessed using the Shapiro–Wilk test. Because the data were not normally distributed, we used a non-parametric statistical Kruskal–Wallis H test to compare the four groups, followed by the Mann–Whitney U test to compare groups two by two. We used a modified formula of the Cohen d test to evaluate the standardised difference between our means. For the correlation study, we used Spearman’s rank correlation coefficient and applied a Bonferroni correction for multiple comparisons.

Receiver operating characteristic (ROC) curve analyses were used to evaluate the discriminating power of the SEA and mini-SEA compared with the MMSE, FAB, verbal fluency test and number of perseverative errors on the WCST. The area under the curve (AUC) was used to measure the overall performance of each ROC curve (with 95% CI). Finally, optimal cut-off points for the SEA were determined by selecting the point on the ROC curve where both sensitivity and specificity were maximised.

Statistical analyses were performed using STATISTICA 6 (http://www.statsoft.com) and MedCalc (http://www.medcalc.org) software.

RESULTS

Demographic data and neuropsychological performances of control subjects, MDD patients, and early and moderate bvFTD patients

All four groups were similar in age and educational level. MMSE and FAB scores were significantly higher in the control group compared with the MDD, early bvFTD and moderate bvFTD groups. The early bvFTD patients had significantly higher scores
for all of the neuropsychological scores than the moderate bvFTD patients. We found no differences between the MDD and early bvFTD groups for any of the neuropsychological tests whereas the MDD group had significantly higher scores than the moderate bvFTD group for the FAB, WCST and verbal fluency tests (see table 1).

Comparison of SEA performances among groups
SEA and mini-SEA scores and SEA subscores were significantly lower in both the early and moderate bvFTD groups compared with controls and the MDD group, except for the reversal learning and behavioural control tests. We found no significant differences in any of the SEA or mini-SEA scores between the early and moderate bvFTD groups. The results of the SEA composite score, reversal learning test and apathy scale were significantly lower in the MDD group compared with controls whereas no differences were found for the mini-SEA, emotion identification, theory of mind test or behavioural control test (table 2, figure 1).

Figure 1A shows scatterplots of the SEA composite scores across groups. Controls and MDD patients had the same score distribution, which was clearly distinct from the distribution observed for both early and moderate bvFTD patients. Figure 2 shows scatterplots of the SEA and mini-SEA scores across the MDD and early bvFTD groups, which demonstrate very little overlap between the groups.

Determining sensitivity, specificity and the optimal SEA cut-off scores for bvFTD diagnosis
The ROC curve showed that the best tests for discriminating MDD from bvFTD patients were the SEA and mini-SEA. The SEA and mini-SEA had cut-off scores of 37.1 and 22.05, respectively, that yielded the highest sensitivities (91.9% and 89.2%, respectively) and specificities (89.5% and 100%, respectively). The AUC was 0.97 for the SEA and 0.98 for the mini-SEA, which indicated that these tests have strong discriminating powers. The AUC for perseverative errors was 0.56 for the WCST, 0.66 for the MMSE, 0.75 for the FAB and 0.71 for verbal fluency (figures 1 and 2).

The sensitivity and specificity for differentiating early bvFTD from MDD were 94.1% and 89.5%, respectively, for the SEA, and 94.1% and 100%, respectively, for the mini-SEA, with cut-offs at 35.28 and 22.05, respectively. These values were similar to those for differentiating MDD patients from moderate bvFTD patients (sensitivity and specificity of 90% and 89.5% for the SEA and 85% and 100% for the mini-SEA, respectively). The AUC for perseverative errors was 0.55 for the WCST with 17.6% sensitivity and 100% specificity at a threshold of 11. The AUC for the MMSE was 0.56 with 76.5% sensitivity and 56.8% specificity at a threshold of 25. The AUC for the FAB was 0.57 with 64.7% sensitivity and 52.6% specificity at a threshold of 16. The AUC for the verbal fluency test was 0.61 with 78.6% sensitivity and 50% specificity at a threshold of 10.

The SEA and mini-SEA had similar diagnostic accuracy powers for distinguishing MDD from early bvFTD (d=3.86 for the SEA and d=5.26 for the mini-SEA) and from moderate bvFTD (d=3.81 and d=2.68). The discrimination abilities of the SEA and mini-SEA were superior to the perseverative errors scores of the WCST (d=−0.32 between MDD and early bvFTD; d=−0.64 between MDD and moderate bvFTD), MMSE (d=0.17 and d=1.12), FAB (d=0.27 and d=1.28) and the verbal fluency test (d=0.45 and d=0.72).

Correlations between SEA and cognitive performances
No correlations were observed between the SEA or mini-SEA subtests and the classic cognitive tests or MDRS, except for the performances of the FAB and the reversal learning test, which were significantly correlated (r=0.79; p<0.0001) in MDD patients.

DISCUSSION
We investigated the ability of the SEA to differentiate bvFTD from major depression. The SEA was used to assess social cognition and emotional processing dysfunctions that are caused by prefrontal lesions. Previous studies have demonstrated a high sensitivity and specificity of the test for differentiating bvFTD from controls or from patients with AD.14 These findings are in accordance to those of other studies that have employed tests assessing executive functions and social cognition.12 However, an unresolved challenge was to understand whether these tests could discriminate bvFTD from depression. Here we show that the SEA and the mini-SEA differentiate both conditions with very high sensitivity and specificity.

Table 1 Characteristics and neuropsychological data of control subjects and patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Control group (n=30)</th>
<th>MDD group (n=19)</th>
<th>Early bvFTD (n=17)</th>
<th>Moderate bvFTD (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>13/17</td>
<td>11/8</td>
<td>11/6</td>
<td>12/8</td>
</tr>
<tr>
<td>Age (years)</td>
<td>66.2±9.9 (42–82)</td>
<td>63.3±8.4 (51–82)</td>
<td>63.1±9.1 (53–83)</td>
<td>66.7±8.3 (51–73)</td>
</tr>
<tr>
<td>Education level</td>
<td>10.7±3.7 (5–16)</td>
<td>10.5±4.7 (2–17)</td>
<td>10.8±3.9 (3–15)</td>
<td>10.4±2.2 (5–17)</td>
</tr>
<tr>
<td>Tests (maximal score)</td>
<td>MMSE (30)</td>
<td>29.2±0.9 (27–30)*</td>
<td>26.7±2.2 (23–30)*</td>
<td>27.1±2.3 (21–30)*</td>
</tr>
<tr>
<td></td>
<td>MDRS (144)</td>
<td>NA</td>
<td>135.3±2.2 (131–141)</td>
<td>119.2±1.2 (92–131)</td>
</tr>
<tr>
<td></td>
<td>FAB (18)</td>
<td>17.1±1 (16–18)*</td>
<td>15.9±1.8 (13–18)*</td>
<td>15.5±1.8 (13–18)</td>
</tr>
<tr>
<td></td>
<td>WCST category (6)</td>
<td>4.7±1.4 (2–6)*</td>
<td>5.1±1.8 (2–6)</td>
<td>3.1±1.9 (0–6)</td>
</tr>
<tr>
<td></td>
<td>WCST perseveration errors</td>
<td>NA</td>
<td>4.7±6.3 (0–14)</td>
<td>5.8±4.9 (0–14)</td>
</tr>
<tr>
<td></td>
<td>WCST attentional errors</td>
<td>NA</td>
<td>2.2±1.7 (0–6)**</td>
<td>0.9±1.5 (0–4)**</td>
</tr>
<tr>
<td></td>
<td>Morphological fluency</td>
<td>10.8±4.5 (2–20)</td>
<td>9.1±3.8 (4–15)</td>
<td>3.9±6.4 (1–30)</td>
</tr>
</tbody>
</table>

Results are expressed as mean±SD (range).
*Significant difference between control subjects and MDD. MMSE: p<0.0001; FAB: p<0.05.
†Significant difference between control subjects and early bvFTD. MMSE: p<0.001; FAB: p<0.001.
‡Significant difference between control subjects and moderate bvFTD. MMSE: p<0.00001; FAB: p<0.00001.
§Significant difference between MDD and moderate bvFTD. MMSE: p<0.0001; FAB: p<0.0001; WCST category: p=0.01; fluency: p=0.005.
**Significant difference between early bvFTD and moderate bvFTD. MMSE: p<0.001; FAB: p<0.005; WCST category: p<0.005; fluency: p<0.005; MDRS: p<0.0001.

bvFTD, behavioural version of frontotemporal dementia; FAB, Frontal Assessment Battery; MDD, major depressive disorder; MDRS, Mattis Dementia Rating Scale; MMSE, Mini-Mental State Examination; WCST, Wisconsin Card Sorting Task.

J Neurol Neurosurg Psychiatry 2012;83:411–416. doi:10.1136/jnnp-2011-301849 413
Several studies have demonstrated that early impairments in social and emotional cognition occur in bvFTD.9–14 Although bvFTD is often misdiagnosed as depression,36 no data on the discriminating power of this type of test for differentiating MDD from bvFTD are available.

Early bvFTD patients and MDD patients can exhibit similar behavioural changes, such as apathy and inertia; apathy is present in 60–90% of bvFTD cases.26–29 In addition to apathy and inertia, MDD patients exhibit executive impairments, such as impairments in concept generation,30 inhibition,31 sustained attention,32 free memory recall,33 working memory,34 and verbal fluency.35 These cognitive processes can also be impaired in bvFTD patients. Early bvFTD can therefore be mistaken for depression, especially when neuropsychological profiles are similar between the conditions.16–17 Moreover, brain imaging can fail to provide useful information for the differential diagnosis; MRIs may be normal in the early stages of bvFTD, whereas fluorodeoxyglucose positron emission tomography can show frontal hypoperfusion/hypometabolism in MDD.36–38

The results of this study demonstrated that the SEA, and particularly the mini-SEA, can efficiently differentiate MDD from bvFTD, even at an early stage of the disease when
neuropsychological tests are still normal. By classifying bvFTD patients as being above or below the normal range in the MDRS, the SEA and mini-SEA differentiated MDD from early bvFTD patients, even though the patient groups did not exhibit any differences in the neuropsychological tests that assess executive functions. For the moderate bvFTD group, the best test for the differential diagnosis remained the SEA compared with classical executive tests. Yet it is noteworthy that the MDRS can remain normal for an extended time during the course of the disease and cannot be considered as a perfect reliable marker of disease severity.

The SEA was constructed by including tasks that are known to be impaired early in bvFTD patients and to be associated with damage to the neural network involving the orbitofrontal and medial prefrontal regions: theory of mind,9–14 reversal learning and behavioural control tests,9,14–16 apathy evaluation14–19 and facial emotion recognition assessment.14–16 We defined a mini-SEA to develop a quick and easy clinical test that could be administered to detect subtle relevant changes that are caused by bvFTD but not by MDD. The mini-SEA takes approximately 30 min to administer. Both the SEA and mini-SEA were similarly effective for differentiating MDD from early bvFTD and can be easily administered in neurological or psychiatric departments. The diagnostic value of the mini-SEA for differentiating early bvFTD from MDD is strengthened by the observations: (1) that the mini-SEA performances were similar between controls and MDD patients, (2) that the SEA and mini-SEA scores did not correlate with severity of depression, which was assessed by the MADRS, (3) that only one patient diagnosed with early bvFTD had a mini-SEA score overlapping with scores of depressive patients, (4) that the SEA was not correlated with scores for tests of executive functions, suggesting that these tests assess distinct processes and (5) that the SEA performances were equally decreased in patients with early and moderate bvFTD, demonstrating the test’s assessment value at the onset of the disease.

Simple and specific tests of emotional and social cognition, including tests of theory of mind, are lacking in their application to FTD. The mini-SEA is an easy and fast tool that can be utilised in neurological or psychiatric departments.

Although pathological data may help to establish the diagnosis of the different subgroups of bvFTD patients, no post-mortem data were available in our cohort. Future autopsy studies are needed to validate the diagnoses and confirm the findings. However, to decrease the risk of false diagnoses, all FTD patients underwent a complete neurological evaluation, including brain imaging, and were followed for at least 18 months to validate their diagnosis by the evolution of clinical symptoms.

**CONCLUSION**

The development of care management strategies needs to improve the differential diagnosis between MDD and bvFTD. Overall, this study showed that the SEA and mini-SEA are useful tools for early cognitive assessments and are relevant for use in daily clinical practice. The SEA can detect specific features of early bvFTD when classic neuropsychological tests are still normal. Finally, the results of this study are in accordance with the growing number of studies that have demonstrated the relevance of early and specific impairments in social and emotional cognition in bvFTD, which may be included in future revisions of bvFTD diagnostic criteria.

**Acknowledgements**

The authors are grateful to Romain Icic, Sophie Guillonet, Floriane Chauvin and Beatrice Garcia for help in the recruitment of patients. Thanks also go to Raphaël Gaillard, Severine Hatif, Magali Seassau and Serge Kinkingnehun for comments on an earlier version of this project.

**Contributors**

MB: design, clinical and experimental data acquisition, analysis and interpretation, and manuscript writing. Statistical analyses were performed by MB. MD: clinical data acquisition and manuscript revision. LCS: manuscript revision and experimental data interpretation. AF: design, manuscript revision and experimental data interpretation. J-PL: manuscript revision, and experimental and clinical data interpretation. PF: manuscript revision and clinical data interpretation. BD: manuscript revision and clinical data interpretation. MS: manuscript writing, clinical and experimental data analysis and interpretation.

**Funding**

MB was supported by the French Ministry of Defence and the National Centre for Scientific Research (CNRS) during his PhD.

**Competing interests**

LCS received speaker honoraria from Lundbeck. J-PL received lecture honoraria from Servier, Sanofi, Pfizer-Wyeth and Pierre Fabre. PF received honoraria from Servier, Lundbeck, Eli Lilly and research grants from Servier. BD has consulted or served on advisory board for Bristol-Myers Squibb, Roche, Elan, Eli Lily, Eisai and Janssen. His institution has received grants from Novartis and Sanofi-Aventis. MS received speaker honoraria from Eisai, Pfizer, Lundbeck, Janssen and Novartis; she belongs to a scientific advisory board for Eisai Company and serves as an associate editor for La Lettre du Neurologue.

**Patient consent**

For patients, all clinical data were obtained during routine clinical work-up in the neurology and psychiatric departments and were extracted solely for the purpose of this study. Thus, according to French legislation, explicit informed consent was waived. However, the regulation concerning electronic filing was followed, and both patients and their relatives were informed that individual data may be used in retrospective clinical research studies. For healthy control subjects, the study was approved by the ethics committee for the protection of persons of the Pitié-Salpêtrière Hospital. All controls received oral and written information and we obtained a signed informed consent form before their participation.

**Ethics approval**

The study was approved by the ethics committee of Pitié-Salpêtrière Hospital, France.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**REFERENCES**


Information for patients from JNNP

**New tool detects type of dementia often confused with depression**

A 30-minute test can reliably detect a type of dementia often misdiagnosed as depression, say researchers, even if the disease is in its early stages.

**What do we know already?**

Behavioural variant of frontotemporal dementia (bvFTD) is a type of dementia that causes changes to behaviour and social interactions which get worse over time. It is often misdiagnosed as depression, particularly in its early stages, as both illnesses share common symptoms, including a lack of emotion, feeling, or interest (apathy).

Physical tests, such as brain scans, often can’t spot bvFTD in its early stages, so doctors use other assessment tools to detect the disease. A newer tool is called the Social Cognition and Emotional Assessment (SEA). It involves a series of tests scoring patients on things such as their level of apathy, how well they recognise emotions by looking at people’s faces in photos, and how well they can infer other people’s moods, thoughts, and feelings. There is also a streamlined version of this tool, called the mini-SEA, which only takes 30 minutes.

Prior studies have shown that the SEA is effective at distinguishing people with bvFTD from those with Alzheimer’s disease. Now researchers have looked at whether the test can reliably distinguish bvFTD from depression.

**What does the new study say?**

Researchers used the SEA and mini-SEA to assess 86 people. Of these, 37 had early or moderate bvFTD, 19 had depression and the remainder had no signs of dementia or psychological illness (the control group). Both versions of the test accurately spotted nearly all the people with bvFTD, as they had lower scores on the tests than those with dementia and those in the control group.

The mini-SEA performed at least as well as the SEA. Only one person diagnosed with early bvFTD had a mini-SEA score overlapping with those of people with depression.
How reliable are the findings?
This was a good-quality study and its findings should be reliable. However, it was fairly small, so we need larger trials to confirm these results.

What does this mean for me?
This study shows that a new assessment tool can quickly and reliably detect bvFTD and distinguish it from depression, which is good news. If you (or someone close to you) has bvFTD, the SEA or mini-SEA may reduce your risk of being misdiagnosed and having inappropriate treatment for depression or another illness. It may also mean that you will be diagnosed more rapidly. And the sooner you are diagnosed the sooner you can start treatment and begin planning for the future.


This summary was prepared by the staff of Best Health, BMJ Group’s patient information service. This information does not replace medical advice. If you have a medical problem please see your doctor.